Trials / Completed
CompletedNCT00125567
Stalevo in Early Wearing-Off Patients
Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 223 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Stalevo (levodopa/carbidopa/entacapone) | Oral, 50-150 mg levodopa four times daily, for up to 2 years |
| DRUG | Levodopa/carbidopa | Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2005-08-01
- Last updated
- 2009-06-22
Locations
19 sites across 6 countries: Denmark, Finland, Germany, Ireland, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00125567. Inclusion in this directory is not an endorsement.